Edition:
India

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

1,152JPY
18 Jul 2019
Change (% chg)

¥-27 (-2.29%)
Prev Close
¥1,179
Open
¥1,174
Day's High
¥1,178
Day's Low
¥1,144
Volume
1,485,700
Avg. Vol
1,132,328
52-wk High
¥2,208
52-wk Low
¥1,144

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Says Application For Initial Marketing Authorization For Mitsubishi Tanabe Pharma's Radicava (Edaravone) Has Been Withdrawn
Wednesday, 29 May 2019 

May 29 (Reuters) - EU Medicines Agency: :EU MEDICINES AGENCY RECOMMENDATIONS FOR MAY 2019.EU MEDICINES AGENCY - APPLICATIONS FOR INITIAL MARKETING AUTHORISATIONS FOR MITSUBISHI TANABE PHARMA’S RADICAVA (EDARAVONE) HAS BEEN WITHDRAWN.  Full Article

Tanabe Research Says U.S. FDA Accepted Its IND Application For TR1801-ADC
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>::TANABE RESEARCH LABORATORIES U.S.A. SAYS FDA ACCEPTED ITS IND APPLICATION FOR TR1801-ADC (MT-8633), AN ADC TARGETING CMET POSITIVE SOLID TUMORS.  Full Article

Pharma Foods International says strategic research collaboration for development of innovative antibody drug
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Pharma Foods International Co Ltd <2929.T>:Says the company and Mitsubishi Tanabe Pharma Corp <<<4508.T>>> announced that we have entered into a strategic research collaboration for the development of the innovative antibody drug to treat autoimmune diseases in October 22, 2018.  Full Article

Health Canada Approves New Drug To Treat Patients With ALS
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - HEALTH CANADA: :HEALTH CANADA APPROVES NEW DRUG TO TREAT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS).HEALTH CANADA - WILL CONTINUE TO WORK WITH MANUFACTURER TO FACILITATE ACCESS TO EDARAVONE UNTIL AUTHORIZED DRUG IS AVAILABLE ON CANADIAN MARKET.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Mitsubishi Tanabe Pharma completes purchase of NeuroDerm
Wednesday, 18 Oct 2017 

Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<>>.Purchase plan was announced on July 24.  Full Article